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results from NHANES III
Abstract
OBJECTIVE: Obesity is associated with a variety of chronic diseases, including cancer, which may
partly be explained by its influence on sex steroid hormone concentrations. Whether different measures
of obesity, i.e., body mass index (BMI), waist circumference, and percent body fat were differentially
associated with circulating levels of sex steroid hormones was examined in 1,265 men, aged
20-90+ years old, attending the morning examination session of the Third National Health and Nutrition
Examination Survey (NHANES III). MATERIALS AND METHODS: Serum hormones were measured
by immunoassay. Weight, height, and waist circumference were measured by trained staff. Percent body
fat was estimated from bioelectrical impedance. Multivariate linear regression was used to estimate
associations between body fatness measures and hormone levels. RESULTS: Total and free testosterone
and sex hormone binding globulin concentrations decreased, whereas total and free estradiol increased
with increasing BMI, waist circumference, and percent body fat (all p trend < 0.05). The magnitude of
change in these hormones was similar for a one-quartile increase in each body fatness measure.
CONCLUSION: Measured BMI, waist circumference, and percent body fat led to similar inferences
about their association with hormone levels in men.
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Abstract 1 
Objective: Obesity is associated with a variety of chronic diseases, including cancer, which may 2 
partly be explained by its influence on sex steroid hormone concentrations. Whether different 3 
measures of obesity, i.e., body mass index (BMI), waist circumference, and percent body fat 4 
were differentially associated with circulating levels of sex steroid hormones was examined in 5 
1,265 men, aged 20 to 90+ years, attending the morning examination session of the Third 6 
National Health and Nutrition Examination Survey (NHANES III). 7 
Methods and Methods: Serum hormones were measured by immunoassay. Weight, height, and 8 
waist circumference were measured by trained staff. Percent body fat was estimated from 9 
bioelectrical impedance. Multivariate linear regression was used to estimate associations 10 
between body fatness measures and hormone levels.  11 
Results: Total and free testosterone and sex hormone binding globulin concentrations 12 
decreased, whereas total and free estradiol increased with increasing BMI, waist circumference, 13 
and percent body fat (all P-trend <0.05). The magnitude of change in these hormones was 14 
similar for a one quartile increase in each body fatness measure. 15 
Conclusion: Measured BMI, waist circumference, and percent body fat led to similar inferences 16 
about their association with hormone levels in men. 17 
 18 
Key words: NHANES III, testosterone, estradiol, obesity 19 
20 
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Introduction 1 
Obesity is a growing problem in Western countries, including the US and an emerging 2 
problem in Asian countries [1]. Obesity leads to health consequences, including a higher risk of 3 
type 2 diabetes mellitus, heart disease, cancer [2, 3], and premature death overall and from 4 
cardiovascular disease and cancer [4]. The precise mechanisms by which obesity influences 5 
chronic disease risk are not entirely clear yet, but one line of evidence involves changes in 6 
circulating levels of sex steroid hormones and sex hormone binding globulin (SHBG) with 7 
obesity, particularly with respect to cancer [5]. More body fat leads to a higher conversion of 8 
testosterone to estradiol by aromatase in fat tissue [6]. This increased conversion suppresses 9 
luteinizing hormone release [7, 8], which results in a reduced production of testosterone by the 10 
Leydig cells. Estrogens also inhibit the activity of 17-α-hydroxylase and 17,20 lyase, thus, 11 
inhibiting intratesticular steroidogenesis [9]. High insulin levels in obese men may inhibit hepatic 12 
SHBG production in HepG2 cells [10]. 13 
Most studies that examined the association between obesity and circulating sex steroid 14 
hormone levels have relied on either body mass index (BMI) or waist circumference (or waist-to-15 
hip ratio) as indicators of body fatness. The association between percentage of body fat and 16 
circulating steroid hormone levels has been less well studied. Although these three measures 17 
are correlated, they do reflect different aspects of obesity [11]. Thus, the aims of this study were 18 
(a) to estimate the associations between three measures of body fatness with serum sex steroid 19 
concentrations overall and after taking into account factors that are both associated with 20 
hormones and body fatness, and (b) to assess differences in the magnitude of the associations 21 
between different measures of body fatness and hormones in a nationally representative 22 
sample of US men. 23 
 24 
 25 
 26 
 27 
Page 5 
Material and Methods 1 
Study population 2 
The Third National Health and Nutrition Examination Survey (NHANES III) is a cross-3 
sectional study that was conducted by the National Center for Health Statistics between 1988 4 
and 1994. It is based on a multistage stratified, clustered probability sample of the US civilian 5 
non-institutionalized population at least two months old [12]. Specific sub-groups of the US 6 
population, including Mexican-Americans, non-Hispanic blacks, and the elderly, were over-7 
sampled to ensure minimum sample sizes. NHANES III was conducted in two phases (1988-8 
1991 and 1991-1994) and unbiased national estimates of health and nutrition characteristics 9 
can be independently produced for each of these two phases. Within each phase, subjects were 10 
randomly assigned to participate in either the morning or afternoon/evening examination 11 
session. More than 33,000 subjects participated in NHANES III. Of these, 1,998 men at least 20 12 
years of age participated in the morning session of phase I. Morning sample participants were 13 
chosen for this hormone study to reduce extraneous variation due to diurnal production of 14 
hormones. For the purpose of our study, serum samples for hormone measurements were still 15 
available for 1,470 of these men. Men with a history of prostate cancer were excluded because 16 
certain treatments may have affected hormone levels (n=12). We further excluded 193 men due 17 
to missing information on BMI (n=1), waist circumference (n=47), percent body fat (n=94), and 18 
other covariates (n=6). Sixteen men were excluded for having missing hormone measurements 19 
and an additional 29 men were excluded for having extreme hormone measurements. The 20 
following cut-points were used to determine extreme hormone measurements and are based on 21 
visual inspection of the distribution of each hormone on the natural log scale: 22 
ln(testosterone)<0.4 (1.5%ile), ln (free testosterone)<-4.0 (1.4%ile), ln (free estradiol)<-1.5 23 
(0.15%ile), ln(SHBG)<1.7 (0.08%ile) and ln (AAG)<2.0 (0.5%ile), leaving 1,265 men for the final 24 
analyses.  25 
Subjects participated in an interview that was conducted at home and in an extensive 26 
physical examination, which included a blood sample collection. Cigarette smoking, alcohol 27 
Page 6 
consumption, and physical activity were assessed using a questionnaire. Height was measured 1 
to the nearest 0.1 cm using a stadiometer and weight was measured to the nearest 0.01 kg 2 
using an electronic digital scale while the participant was wearing foam slippers and paper shirt 3 
and pants. BMI was calculated as weight in kilograms divided by the square of height in meters. 4 
Waist circumference was measured at the iliac crest to the nearest 0.1 cm. A Valhalla Scientific 5 
Body Composition Analyzer (model 1990B; Valhalla Scientific, Inc., San Diego, CA) was used to 6 
measure whole body electrical resistance. Validated prediction equations using height and 7 
weight were used to convert whole body electrical resistance at 50 kHz to percent body fat [13].  8 
 9 
Measurement of serum sex steroid hormones and SHBG 10 
Blood was drawn after an overnight fast for participants in the morning sample during 11 
either an examination at a Medical Examination Center or during an abbreviated examination at 12 
home. After centrifugation, serum was aliquotted and stored at -70°C until they were pulled from 13 
the freezers for this project. The serum samples were shipped on dry ice directly from the 14 
National Center for Health Statistics’ main repository in Atlanta, GA, to the assay laboratory. 15 
Serum hormone concentrations were measured in the laboratory of Dr. Nader Rifai at 16 
Children’s Hospital in Boston, MA. Competitive electrochemiluminescence immunoassays on 17 
the 2010 Elecsys autoanalyzer (Roche Diagnostics, Indianapolis, IN) were used to quantify 18 
serum testosterone, estradiol, and SHBG. Androstanediol glucuronide was measured by an 19 
enzyme immunoassay (Diagnostic Systems Laboratories, Webster, TX). The participant 20 
samples were randomly ordered for testing and the laboratory technicians were blinded to the 21 
identities and characteristics of the participants. The lowest detection limits of the assays were: 22 
testosterone 0.02 ng/mL, estradiol 5 pg/mL, androstanediol glucuronide 0.33 ng/mL, and SHBG 23 
3 nmol/L. The coefficients of variation for quality control specimens included during the analyses 24 
of the NHANES III specimens were as follows: testosterone 5.9% and 5.8% at 2.5 and 5.5 25 
ng/mL; estradiol 6.5% and 6.7% at 102.7 and 474.1 pg/mL; androstanediol glucuronide 9.5% 26 
and 5.0% at 2.9 and 10.1 ng/mL; and SHBG 5.3% and 5.9% at 5.3 and 16.6 nmol/L. In addition, 27 
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we ran quality control samples with a mean estradiol concentration of 39.4 pg/mL, which is in 1 
the range of typical male estradiol concentrations; the intra-assay CV% was 5.2% and the inter-2 
assay CV% was 2.5%. Free testosterone concentration was estimated from measured total 3 
testosterone, SHBG, and albumin (already available in the NHANES III public use database) 4 
[14]; free estradiol was calculated from total estradiol, SHBG, and albumin [15]. 5 
 6 
Statistical analysis 7 
 All statistical analyses were performed using SUDAAN [16] as implemented in SAS v.9.1 8 
(Cary, NC). Sampling weights were applied to take into account selection probabilities, over-9 
sampling, non-response, and differences between the sample and the total US population [12].  10 
We computed the Spearman correlation coefficient adjusted for age between the 11 
different hormones. Linear regression models were used to estimate the association between 12 
quartiles of the three measures of body fatness – BMI, waist circumference, and percent body 13 
fat – and hormone concentrations. Because hormone and SHBG concentrations were not 14 
normally distributed, we used log-transformed data. In Model 1, we adjusted for age (1-year 15 
increments) and race/ethnicity (non-Hispanic black, non-Hispanic white, Mexican-American, 16 
other). To evaluate the possibly confounding effects of factors that influence hormone 17 
concentrations, in Model 2 we included age and race/ethnicity as well as cigarette smoking 18 
(never smoker, former smoker, current smoker), alcohol consumption (never drinker, ≤1 19 
drink/week, >1 drink/week to <1 drink/day, 1+ drink/day), and physical activity (moderate or 20 
vigorous physical activity on 0 times/week, <3 times/week, ≥3 to <8 times/week, > 8 21 
times/week). When Model 2 was further adjusted for serum cotinine and a spline term for age at 22 
42 years, the inferences did not significantly change; therefore, we did not include these factors 23 
in the final Model 2. In Model 3, we adjusted for the factors in Model 2 plus mutually adjusted 24 
testosterone, estradiol, and SHBG because these hormones compete for binding with SHBG, 25 
and adjusted free testosterone for total estradiol and free estradiol for total testosterone. We 26 
compared geometric mean concentrations of hormones and SHBG across quartiles of BMI, 27 
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waist circumference, and percent body fat using analysis of variance. We estimated the slope of 1 
the change in the natural logarithm hormone concentration with increasing body fatness by 2 
entering into the models an ordinal variable with values of 1, 2, 3, and 4 corresponding to 3 
quartile of each body fatness measure; we tested its coefficient using the Wald test. We used 4 
quartiles to compare the strengths of the association using a comparable scaling of each body 5 
fat measure; one unit change in BMI, waist circumference, and percent body fat are not 6 
comparable in scale, but taking the distribution of these fat measures, which each captures 7 
extent of body fatness, and dividing them based on achieving equal numbers of men should 8 
yield approximately comparable scaling. 9 
While each of the three anthropometric measures reflects the underlying extent of body 10 
fat, each is measured with error, although the sources of errors may not be the same. Thus, we 11 
cross-classified the men based on quartiles of two of the three body fatness measures at a time 12 
and estimated the geometric mean hormone concentrations for men in the lowest quartile on 13 
both of the measures, the highest quartile on both of the measures, and all other combinations. 14 
We then compared the geometric means for the combinations to the means for the individual 15 
measures. 16 
Finally, we computed the changes in BMI, waist circumference and percent body fat that 17 
were associated with a 2% decline in the geometric mean of total testosterone, free 18 
testosterone, total estradiol, free estradiol, SHBG and androstanediol glucuronide. These 19 
estimates were calculated based on geometric mean hormone levels for a 50-year old, white 20 
man who is a non-smoker, in the second quartile of alcohol consumption and physical activity. 21 
All significance tests were two-sided; p<0.05 was considered to be statistically 22 
significant. 23 
The protocols for the conduct of NHANES III were approved by the Institutional Review 24 
Board of the National Center for Health Statistics, US Centers for Disease Control and 25 
Prevention. Informed consent was obtained from all participants. The measurement of sex 26 
steroid hormones in these stored serum specimens was approved by Institutional Review 27 
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Boards at the Johns Hopkins Bloomberg School of Public Health and the National Center for 1 
Health Statistics, US Centers for Disease Control and Prevention. 2 
 3 
Results  4 
The distribution of baseline characteristics in the study population after applying 5 
sampling weights is shown in Table 1. The prevalence of current smoking was 34.0% and 6 
17.4% of men consumed at least one alcoholic drink per day. One third of men had moderate or 7 
vigorous activity eight or more times per week; this included walking or stair climbing. The 8 
prevalence of obesity was 17.4% based on BMI (≥ 30 kg/m2), 24.5% based on waist 9 
circumference (≥ 102 cm), and 48.8% based on percent body fat [≥ 25%; see [17]]. The partial 10 
Spearman correlation coefficients (adjusted for age and race/ethnicity) between the three 11 
measures of body fatness were: BMI and waist circumference: r=0.93; BMI and percent body 12 
fat: r=0.68; and waist circumference and percent body fat: r=0.71.  13 
Almost all hormones were statistically significantly correlated, although the strength of 14 
correlation differed. Correlation coefficients of total testosterone with free testosterone, total and 15 
free estradiol, androstanediol glucuronide, and SHBG were 0.75, 0.43, 0.15, 0.11, 0.63, 16 
respectively (all p-values <0.0001); correlation coefficients of free testosterone with total and 17 
free estradiol, androstanediol glucuronide, and SHBG were 0.49, 0.47, 0.16, 0.06, respectively 18 
(all p-values <0.0001; SHBG: p=0.046); correlation coefficients of total estradiol with free 19 
estradiol, androstanediol glucuronide, and SHBG were 0.89, 0.09, and 0.11, respectively (all p-20 
values <0.0001; androstanediol glucoronide p=0.003); correlation coefficients of free estradiol 21 
with androstanediol glucuronide and SHBG were 0.07 (p=0.01) and -0.27 (p <0.0001), 22 
respectively; correlation between androstanediol glucuronide and SHBG was 0.0007 (p-value 23 
0.98). 24 
 25 
Total and Free Testosterone 26 
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Total and free testosterone concentrations decreased with increasing extent of each 1 
body fatness measure (Tables 2, 3, 4). For total testosterone, the decline in concentration with 2 
increasing body fatness was attenuated after further adjustment for smoking, alcohol 3 
consumption, and physical activity (Model 2) and was even more greatly attenuated after further 4 
adjustment for total estradiol and SHBG (Model 3). For free testosterone, the size of the decline 5 
in concentration with increasing body fatness was similar in Models 1 and 3, but less steep in 6 
Model 2. In the fully adjusted model (Model 3), the extent of the decline in total testosterone and 7 
also in free testosterone concentrations was similar for a one-quartile change in BMI (Table 2), 8 
waist circumference (Table 3), and percent body fat (Table 4). 9 
 10 
Total and Free Estradiol 11 
Total estradiol concentration did not increase with increasing extents of any of the three 12 
measures of body fatness after adjustment for age and race/ethnicity (Model 1). However, in the 13 
fully adjusted model (Model 3), total estradiol statistically significantly increased with increasing 14 
BMI (Table 2) and waist circumference (Table 3). For percent body fat (Table 4), we observed a 15 
statistically significant increasing association after adjusting for the modifiable factors (Model 2), 16 
and an even stronger increasing association after further adjusting for total testosterone and 17 
SHBG (Model 3). In Model 3, the slope of the increase in total estradiol concentration with 18 
increasing body fatness was similar for BMI, waist circumference, and percent body fat. Free 19 
estradiol concentration increased with increasing extent of body fatness in all three models; the 20 
slope of the increase was greatest for Model 3, and was comparable for BMI (Table 2), waist 21 
circumference (Model 3), and percent body fat (Model 4). 22 
 23 
SHBG 24 
SHBG concentration decreased with increasing extent of each measure of body fatness 25 
in all models (Tables 2, 3, 4). The extent of the decline in concentration was similar for Models 1 26 
and 2, but was attenuated after additional adjustment for total testosterone and total estradiol 27 
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(Model 3). In Model 3, the extent of the decline was similar for BMI (Table 2) and waist 1 
circumference (Table 3), but less steep for percent body fat (Table 4). 2 
 3 
Androstanediol glucuronide 4 
For each measure of body fatness, androstanediol glucuronide concentration was lowest 5 
in the bottom quartile and equally high in the top three quartiles. The associations were the 6 
same for Models 1 and 2. The slope of the increase in concentration was higher and statistically 7 
significant for waist circumference (Table 3) and percent body fat (Table 4) only.  8 
 9 
 For each hormone and SHBG, we examined whether the patterns differed by age; 10 
however, the patterns were generally similar across age (data not shown). 11 
 When we cross-classified the men by quartiles of any two of the body fatness measures, 12 
the geometric mean hormone concentrations for men in the top quartile of two of the measures 13 
and for men in the bottom quartile of two of the measures were similar to the geometric mean 14 
concentrations when using only one of the measures (data not shown).  15 
Finally, we estimated how much the men’s BMIs, waist circumferences and percents 16 
body fat would have to differ to result in a 2% lower geometric mean hormone concentrations 17 
(Table 5). Lower total and free testosterone and SHBG concentrations were observed among 18 
men with higher body fatness, whereas lower total and free estradiol, and androstanedial 19 
glucuronide concentrations were observed among men with lower body fatness. Body fatness 20 
was most strongly associated with total testosterone and SHBG concentrations such that a 21 
higher BMI of less than 1 kg/m2, a higher waist circumference of approximately 2 cm, or a 1% 22 
higher body fat percentage would result in a 2% lower geometric mean concentration of these 23 
two analytes. 24 
 25 
 26 
 27 
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Discussion 1 
We evaluated the associations between body fatness and circulating concentrations of 2 
sex steroid hormones and SHBG in a nationally representative sample of US men 20+ years 3 
old. We used three measures of body fatness: BMI, waist circumference, and percent body fat. 4 
BMI is the most often used measure of body fatness because it is easy to assess. However, it is 5 
an imperfect indicator of extent of fat mass because BMI captures both fat and lean mass. 6 
Although BMI tends to stay constant with age, lean body mass declines and fat mass increases 7 
[18, 19]. Thus, in younger men, a high BMI is more likely to reflect lean body mass than in older 8 
men [19]. Nevertheless, BMI is a strong predictor of cardiovascular, total cancer, and all cause 9 
mortality [20]. Waist circumference is considered to be a good indicator of central adiposity and, 10 
thus, intra-abdominal fat mass [21], and it has been shown to be a better predictor of 11 
cardiovascular disease risk than waist-to-hip ratio in men [22]. Additionally, in the European 12 
Prospective Investigation into Cancer and Nutrition (EPIC), it has been shown that both general 13 
adiposity and abdominal adiposity were associated with the risk of death, but also supported the 14 
use of waist circumference or WHR in addition to BMI in assessing the risk of death [4]. The 15 
third indicator that we used in this study was the percentage of total mass that is fat mass. 16 
Percent body fat is less frequently used in epidemiologic studies because its measurement 17 
requires specialized equipment and is more labor intensive [11]. These three measures reflect 18 
different aspects of obesity [11], yet are correlated. Thus, our goal was to examine in detail and 19 
compare their associations with hormone levels. 20 
 We observed a decrease in total testosterone concentration with increasing body 21 
fatness, which is consistent with previous studies that used either BMI, waist circumference, or, 22 
in some instances, percent body fat [18, 23-28]. Adjustment for smoking, alcohol drinking, and 23 
physical activity, each of which is associated with hormone levels [29], slightly reduced the 24 
slope of the decline in concentration for each body fatness measure. Because body fatness and 25 
testosterone are both associated with estradiol and SHBG, further adjustment for estradiol and 26 
SHBG produced a substantial attenuation of the slope. The slopes of the declines in total 27 
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testosterone concentration were comparable for each of the three measures of body fatness. 1 
Free testosterone concentration also declined with all three measures of body fatness and the 2 
extent of the decline was similar across all three measures. Only a slight attenuation was 3 
observed after further adjustment for smoking, alcohol, and physical activity and further 4 
adjustment for total estradiol enhanced the slopes. The slope of the decline after adjustment for 5 
age and race/ethnicity was less steep than for total testosterone. However, after multivariable 6 
adjustment, including total estradiol, the slopes for free and total testosterone were comparable. 7 
These results suggest that investigators should consider taking into account other modifiable 8 
risk factors and other hormones when studying the links among body fatness, total testosterone, 9 
and chronic diseases. 10 
We observed an increase in total estradiol concentration with increasing BMI, waist 11 
circumference, and percent body fat primarily after taking into account testosterone and SHBG 12 
concentrations, both of which are correlates of estradiol and body fatness. The magnitude of the 13 
increase in total estradiol concentration was about the same for each measure of body fatness 14 
after multivariable adjustment. Each measure of body fatness was associated with free 15 
estradiol; the association was enhanced with multivariable adjustment. Although it is well 16 
recognized that aromatase in fat tissue catalyzes the conversion of testosterone to estradiol [6], 17 
not all studies that have evaluated the extent of body fatness and circulating estradiol have 18 
observed a direct association. Vermeulen et al. [30] reported higher estradiol concentrations in 19 
obese European men (age 25-62 years) compared with non-obese men, but no association was 20 
observed in an Italian study [23]. Muller et al. [31] observed a statistically significant increase in 21 
estradiol concentration over quartiles of BMI and waist circumference; this study adjusted for 22 
age, smoking, alcohol consumption, physical activity, and the presence of chronic diseases. In a 23 
US study, estradiol was not statistically associated with body fat or waist circumference in 24 
middle-aged men [32] and no association has been observed in other US studies [25, 33]. A 25 
Greek study reported a 77% higher estradiol concentration in elderly men with BMI ≥ 30 26 
compared with BMI < 27 kg/m2, although this difference was of marginal statistical significance 27 
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[34]. One reason for differences among studies might be that studies did not consistently adjust 1 
for confounding factors; our results suggest that taking into account testosterone and SHBG is 2 
needed to observe a clear association between body fatness and total estradiol.  3 
An inverse association between obesity and SHBG has been reported consistently [23, 4 
24, 26-28, 33, 35]. Some studies have observed associations for BMI and/or waist 5 
circumference but not fat mass [18, 25, 32]. We observed inverse associations between each of 6 
the three measures of body fatness and SHBG. For each, the association was substantially 7 
attenuated after taking into account total testosterone and total estradiol; the association was 8 
weakest for percent body fat, although it remained statistically significant. It might be that SHBG 9 
is more strongly affected by abdominal than overall obesity. 10 
Androstanediol glucuronide is a dihydrotestosterone metabolite that is considered an 11 
indicator of testosterone to dihydrotestosterone conversion by 5-alpha-reductases. We 12 
observed a non-linear association between the measures of body fatness and androstanediol 13 
glucuronide concentration; levels were equally higher in the top three quartiles of each measure 14 
of body fatness. However, the magnitude of the association was weaker and not significant for 15 
BMI. This latter result is compatible with previous studies that did not find associations between 16 
BMI and blood levels of androstanediol glucuronide [33, 36], although high BMI was related to 17 
higher levels of androstanediol glucuronide in male EPIC participants [37]. Based on their own 18 
and the observations of another study [38], Suzuki et al. [37] hypothesized that excess body 19 
weight might stimulate peripheral androgen metabolism, while lowering overall testosterone 20 
concentrations. 21 
To get a better sense of just how large of a change in each measure of body fatness 22 
would be necessary to yield the same magnitude of change in any given hormone concentration 23 
and to determine which hormones are more greatly affected by body fatness for the purpose of 24 
assessing public health impact, we estimated the change in each of the measures of body 25 
fatness that would yield a 2% change in the geometric mean hormone concentration. Total 26 
testosterone and SHBG concentrations were higher with slightly lower BMI, waist 27 
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circumference, and percent body fat, implying that even a modest loss of body fat could improve 1 
testosterone and SHBG profiles. In contrast, big decreases in body fatness would be needed to 2 
reduce total estradiol and androstanediol glucuronide. 3 
The strengths of our study include the standardized measurement of the three measures 4 
of body fatness, the measurement of hormone levels with good precision, and the availability of 5 
modifiable correlates of hormones in a large, well-characterized group of men who are 6 
representative of the general US population. Limitations of our study include the cross-sectional 7 
nature of the association such that we cannot determine whether body fatness affects hormones 8 
or vice versa, and the single measurement hormone levels, which may not represent the men’s 9 
usual levels. 10 
In conclusion, our results suggest that measured BMI, waist circumference, and percent 11 
body fat lead to similar inferences about the association between body fatness and hormone 12 
levels in men. Investigators should use whichever of the measures of body fatness that is most 13 
feasible for their study and is appropriate for the outcome (for example, if diabetes is the 14 
outcome the investigators may be most interested in measuring waist circumference). 15 
Additionally, investigators should consider taking into account other modifiable risk factors and 16 
other hormones when studying the links among body fatness, total testosterone or SHBG, and 17 
chronic diseases. 18 
 19 
 20 
 21 
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Unweighted Mean or 
sample size percentage (SE)1 IQR
Age, y 1,265 41.6 (0.7) 27-62
Race/ethnicity, %
   Non-Hispanic White 590 78.6 (3.1)
   Non-Hispanic Black 298 8.9 (1.3)
   Mexican-American 326 5.0 (0.8)
   Other 51 7.4 (2.1)
Body fat, % 1,265 24.9 (0.3) 21.8-29.4
Body mass index, kg/m2 1,265 26.3 (0.2) 22.7-28.7
Waist circumference, cm 1,265 94.4 (0.6) 83.5-102.3
Cigarette smoking, %
   Never 433 34.5 (2.3)
   Former 424 31.5 (2.9)
   Current 408 34.0 (2.1)
Alcohol consumption, %
   0 drinks/month 461 30.6 (2.5)
   0.1 to 4 drinks/month 224 17.0 (1.6)
   4.1 to 29.9 drinks/month 372 35.0 (2.1)
   ≥ 30 drinks/month 208 17.4 (2.6)
Frequency of physical activity, %
   0 times/week 162 8.0 (1.3)
   0.1 to 2.9 times/week 388 29.3 (2.0)
   3 to 7.9 times/week 357 29.8 (1.2)
   ≥ 8 times/week 358 32.9 (2.9)
Total testosterone (ng/mL) 2 1,265 5.59 (0.09) 3.8-6.5
Total estradiol (pg/mL) 2 1,265 37.3 (0.7) 28.6-43.1
SHBG (nmol/L) 2 1,265 37.7(0.7) 26.1-51.5
Androstanediol glucuronide (ng/mL) 2 1,265 14.4 (0.5) 7.0-15.9
Free testosterone (ng/mL) 2 1,265 0.112 (0.002) 0.07-0.13
Free estradiol (pg/mL) 2 1,265 0.962 (0.02) 0.71-1.1
      
concentrations of 1,265 adult men who participated in 
the morning examination session of Phase I of the Third 
National Health and Nutrition Examination Survey 
(NHANES III)
Subject characteristics
SE: standard error; IQR: interquartile range
1sampling weights were applied
2geometric mean
Quartile
Range 
(kg/m2) Mean 95% CI Mean 95% CI Mean 95% CI
Q1 ≤22.9 6.16 (5.96, 6.37) 6.07 (5.85, 6.30) 5.55 (5.36, 5.75)
Q2 23.0-25.3 5.73 (5.49, 5.98) 5.64 (5.40, 5.88) 5.48 (5.33, 5.65)
Q3 25.4-28.7 5.13 (4.91, 5.37) 5.19 (4.96, 5.43) 5.35 (5.19, 5.53)
Q4 > 28.7 4.28 (4.12, 4.44) 4.38 (4.23, 4.52) 4.74 (4.58, 4.91)
Slope4, p-
trend -0.12 <0.001 -0.106 <0.001 -0.048 <0.001
Q1 ≤22.9 0.11 (0.106, 0.114) 0.108 (0.104, 0.111) 0.109 (0.105, 0.113)
Q2 23.0-25.3 0.111 (0.106, 0.116) 0.109 (0.104, 0.115) 0.11 (0.106, 0.114)
Q3 25.4-28.7 0.106 (0.102, 0.110) 0.107 (0.102, 0.111) 0.108 (0.104, 0.112)
Q4 > 28.7 0.097 (0.092, 0.101) 0.099 (0.095, 0.103) 0.096 (0.093, 0.100)
Slope4, p-
trend -0.042 0.001 -0.028 0.02 -0.037 0.002
Q1 ≤22.9 35.87 (34.29, 37.53) 35.3 (34.08, 36.57) 34.19 (32.69, 35.77)
Q2 23.0-25.3 36.2 (34.60, 37.87) 35.69 (34.19, 37.27) 34.95 (33.68, 36.28)
Q3 25.4-28.7 34.64 (32.79, 36.59) 35.16 (33.35, 37.07) 35.13 (33.51, 36.82)
Q4 > 28.7 37.11 (35.62, 38.67) 37.64 (35.91, 39.45) 39.73 (38.05, 41.48)
Slope4, p-
trend 0.006 0.5 0.018 0.1 0.044 <0.001
Q1 ≤22.9 0.85 (0.81, 0.90) 0.84 (0.80, 0.87) 0.82 (0.78, 0.85)
Q2 23.0-25.3 0.9 (0.85, 0.95) 0.89 (0.85, 0.94) 0.88 (0.84, 0.93)
Q3 25.4-28.7 0.9 (0.85, 0.95) 0.91 (0.87, 0.96) 0.92 (0.88, 0.96)
Q4 > 28.7 1.03 (0.98, 1.08) 1.04 (0.99, 1.10) 1.08 (1.03, 1.13)
Slope4, p-
trend 0.056 <0.001 0.066 <0.001 0.086 <0.001
Q1 ≤22.9 43.38 (40.42, 46.55) 43.29 (40.50, 46.28) 38.59 (36.60, 40.69)
Q2 23.0-25.3 37.45 (35.17, 39.87) 36.89 (34.85, 39.05) 34.95 (33.35, 36.64)
Q3 25.4-28.7 32.52 (30.43, 34.77) 32.62 (30.46, 34.94) 32.88 (31.01, 34.88)
Q4 > 28.7 26.71 (25.43, 28.05) 27.06 (25.71, 28.47) 31.75 (30.06, 33.54)
Slope4, p-
trend -0.159 <0.001 -0.153 <0.001 -0.066 <0.001
Q1 ≤22.9 10.97 (10.02, 12.00) 10.98 (10.03, 12.02)
Q2 23.0-25.3 12.45 (11.16, 13.90) 12.6 (11.34, 14.01) Not
Q3 25.4-28.7 12.49 (11.92, 13.09) 12.43 (11.72, 13.18) Applicable
Q4 > 28.7 12.04 (10.93, 13.25) 11.98 (10.86, 13.21)
Slope4, p-
trend 0.028 0.1 0.026 0.2
2Model 2: adjusted for age and race/ethnicity, smoking, alcohol consumption, physical activity
3Model 3: same as model 2 plus testosterone, estradiol, and SHBG mutually adjusted and free testosterone and free estradiol 
mutually adjusted
Free testosterone (ng/mL)
Total estradiol (pg/mL)
Free estradiol (pg/mL)
Sex hormone binding globulin (nmol/L)
Androstanediol glucuronide (ng/mL)
1Model 1: adjusted for age and race/ethnicity; 
Total testosterone (ng/mL)
Table 2. Sex steroid hormone and SHBG concentrations by quartiles of BMI in men, 
NHANES III, 1988-1991
BMI Model 11 Model 22 Model 33
4Per 1 quartile change in BMI
Quartile Range (cm) Mean 95% CI Mean 95% CI Mean 95% CI
Q1 ≤84.9 6.48 (6.18, 6.79) 6.34 (6.01, 6.69) 5.65 (5.48, 5.83)
Q2 85.0-92.8 5.58 (5.36, 5.82) 5.55 (5.34, 5.77) 5.5 (5.31, 5.69)
Q3 92.9-101.7 5.01 (4.68, 5.35) 5.05 (4.77, 5.34) 5.26 (5.10, 5.43)
Q4 >101.7 4.26 (4.07, 4.47) 4.34 (4.14, 4.56) 4.73 (4.57, 4.90)
Slope4, p-
trend -0.136 <0.001 -0.123 <0.001 -0.058 <0.001
Q1 ≤84.9 0.114 (0.110, 0.117) 0.112 (0.108, 0.115) 0.111 (0.107, 0.115)
Q2 85.0-92.8 0.108 (0.104, 0.112) 0.108 (0.103, 0.112) 0.109 (0.105, 0.114)
Q3 92.9-101.7 0.104 (0.098, 0.111) 0.105 (0.099, 0.110) 0.106 (0.102, 0.110)
Q4 >101.7 0.097 (0.092, 0.101) 0.099 (0.094, 0.103) 0.097 (0.093, 0.100)
Slope4, p-
trend -0.052 <0.001 -0.04 0.001 -0.045 <0.001
Q1 ≤84.9 36.93 (35.44, 38.48) 36.31 (34.91, 37.76) 34.71 (33.18, 36.31)
Q2 85.0-92.8 35.02 (33.28, 36.85) 34.95 (33.41, 36.56) 34.4 (32.82, 36.05)
Q3 92.9-101.7 34.67 (32.19, 37.36) 35.02 (32.96, 37.22) 35.34 (33.72, 37.04)
Q4 >101.7 37.15 (35.51, 38.86) 37.49 (35.76, 39.29) 39.53 (38.23, 40.87)
Slope4, p-
trend 0.001 0.9 0.01 0.3 0.042 <0.001
Q1 ≤84.9 0.87 (0.82, 0.92) 0.86 (0.82, 0.90) 0.83 (0.78, 0.87)
Q2 85.0-92.8 0.87 (0.82, 0.92) 0.87 (0.83, 0.92) 0.86 (0.82, 0.91)
Q3 92.9-101.7 0.91 (0.84, 0.98) 0.92 (0.86, 0.98) 0.92 (0.87, 0.98)
Q4 >101.7 1.03 (0.99, 1.08) 1.04 (0.99, 1.09) 1.08 (1.04, 1.12)
Slope4, p-
trend 0.056 <0.001 0.063 <0.001 0.085 <0.001
Q1 ≤84.9 45.42 (41.75, 49.42) 44.93 (41.38, 48.78) 38.98 (36.97, 41.10)
Q2 85.0-92.8 36.53 (34.30, 38.89) 36.27 (34.33, 38.32) 34.57 (33.11, 36.09)
Q3 92.9-101.7 31.75 (29.71, 33.94) 32.04 (29.92, 34.32) 32.92 (31.47, 34.44)
Q4 >101.7 26.66 (25.48, 27.88) 26.9 (25.76, 28.08) 31.66 (30.32, 33.05)
Slope4, p-
trend -0.174 <0.001 -0.166 <0.001 -0.068 <0.001
Q1 ≤84.9 10.52 (9.50, 11.65) 10.49 (9.47, 11.61)
Q2 85.0-92.8 12.17 (11.23, 13.19) 12.22 (11.23, 13.29) Not
Q3 92.9-101.7 12.76 (11.86, 13.72) 12.72 (11.69, 13.84) Applicable
Q4 >101.7 12.6 (11.59, 13.71) 12.63 (11.54, 13.82)
Slope4, p-
trend 0.058 0.01 0.06 0.02
2Model 2: adjusted for age and race/ethnicity, smoking, alcohol consumption, physical activity
3Model 3: same as model 2 plus testosterone, estradiol, and SHBG mutually adjusted and free testosterone and free estradiol 
mutually adjusted
4Per 1 quartile change in waist circumference
Free testosterone (ng/mL)
Total estradiol (pg/mL)
Free estradiol (pg/mL)
Sex hormone binding globulin (nmol/L)
Androstanediol glucuronide (ng/mL)
1Model 1: adjusted for age and race/ethnicity
Total testosterone (ng/mL)
Table 3. Sex steroid hormone and SHBG concentrations by quartiles of waist 
circumference in men, NHANES III, 1988-1991
Waist circumference Model 11 Model 22 Model 33
Quartile Range (%) Mean 95% CI Mean 95% CI Mean 95% CI
Q1 ≤21.4 6.06 (5.77, 6.37) 5.95 (5.66, 6.25) 5.49 (5.28, 5.71)
Q2 21.5-24.9 5.63 (5.33, 5.95) 5.62 (5.35, 5.90) 5.54 (5.35, 5.74)
Q3 25.0-28.6 5.12 (4.90, 5.36) 5.15 (4.94, 5.37) 5.34 (5.22, 5.47)
Q4 >28.6 4.42 (4.18, 4.68) 4.5 (4.27, 4.74) 4.75 (4.57, 4.94)
Slope4, p-
trend -0.104 <0.001 -0.092 <0.001 -0.047 <0.001
Q1 ≤21.4 0.109 (0.106, 0.113) 0.108 (0.104, 0.112) 0.109 (0.104, 0.114)
Q2 21.5-24.9 0.111 (0.104, 0.118) 0.11 (0.104, 0.117) 0.111 (0.106, 0.115)
Q3 25.0-28.6 0.107 (0.103, 0.111) 0.107 (0.104, 0.111) 0.108 (0.104, 0.111)
Q4 >28.6 0.096 (0.091, 0.101) 0.097 (0.093, 0.102) 0.095 (0.091, 0.100)
Slope4, p-
trend -0.044 0.011 -0.033 0.006 -0.043 0.001
Q1 ≤21.4 35.52 (33.82, 37.30) 35.09 (33.61, 36.64) 34.3 (32.46, 36.23)
Q2 21.5-24.9 35.48 (33.06, 38.08) 35.59 (33.69, 37.60) 34.74 (33.28, 36.27)
Q3 25.0-28.6 35.69 (33.52, 38.01) 35.59 (33.82, 37.45) 35.52 (33.95, 37.15)
Q4 >28.6 37 (35.58, 38.48) 37.45 (35.94, 39.02) 39.33 (37.67, 41.06)
Slope4, p-
trend 0.013 0.145 0.02 0.03 0.043 0.001
Q1 ≤21.4 0.85 (0.81, 0.90) 0.85 (0.81, 0.89) 0.83 (0.79, 0.88)
Q2 21.5-24.9 0.89 (0.83, 0.96) 0.89 (0.84, 0.95) 0.89 (0.84, 0.94)
Q3 25.0-28.6 0.93 (0.87, 1.00) 0.93 (0.88, 0.98) 0.93 (0.89, 0.98)
Q4 >28.6 1 (0.95, 1.05) 1.01 (0.97, 1.05) 1.03 (0.99, 1.09)
Slope4, p-
trend 0.051 <0.001 0.057 <0.001 0.071 <0.001
Q1 ≤21.4 42.73 (39.74, 45.95) 42.18 (39.54, 45.00) 37.83 (36.30, 39.42)
Q2 21.5-24.9 35.87 (34.56, 37.23) 35.84 (34.73, 36.98) 33.89 (32.58, 35.24)
Q3 25.0-28.6 31.63 (29.53, 33.87) 31.91 (29.80, 34.18) 32.46 (30.97, 34.02)
Q4 >28.6 28.99 (27.12, 30.99) 29.14 (27.37, 31.02) 33.75 (32.20, 35.38)
Slope4, p-
trend -0.129 <0.001 -0.122 <0.001 -0.04 0.003
Q1 ≤21.4 10.6 (9.67, 11.62) 10.56 (9.65, 11.56)
Q2 21.5-24.9 12.52 (11.48, 13.64) 12.57 (11.39, 13.86) Not
Q3 25.0-28.6 12.16 (11.37, 13.00) 12.24 (11.43, 13.11) Applicable
Q4 >28.6 12.73 (11.68, 13.88) 12.64 (11.62, 13.75)
Slope4, p-
trend 0.052 0.019 0.052 0.03
2Model 2: adjusted for age and race/ethnicity, smoking, alcohol consumption, physical activity
3Model 3: same as model 2 plus testosterone, estradiol, and SHBG mutually adjusted and free 
testosterone and free estradiol mutually adjusted
4Per 1 quartile change in percent body fat
Free testosterone (ng/mL)
Total estradiol (pg/mL)
Free estradiol (pg/mL)
Sex hormone binding globulin (nmol/L)
Androstanediol glucuronide (ng/mL)
1Model 1: adjusted for age and race/ethnicity
Total testosterone (ng/mL)
Table 4. Sex steroid hormone and SHBG concentrations by quartiles of 
percent body fat in men, NHANES III, 1988-1991
Percent body fat Model 11 Model 22 Model 33
BMI (kg/m2)
Waist circumference 
(cm) Percent body fat (%)
Total testosterone 0.8 2 1.1
Free testosterone 2.3 5.2 2.7
Total estradiol -4.3 -14.9 -5.1
Free estradiol -1.4 -3.7 -1.8
SHBG 0.7 1.6 0.9
Androstanediol 
glucuronide -6.7 -7.3 -1.9
Table 5. Change in BMI, waist circumference, and percent body fat associated with a 2% 
decline in the geometric mean concentration of total testosterone, free testosterone, total 
estradiol, free estradiol, SHBG and androstanediol glucuronide in men, NHANES III, 
1988-1991
Change in body fatness1
1Estimates are calculated based on the geometric mean testosterone concentration for a 50-year 
old, white man who is a non-smoker, in the second quartile of alcohol consumption and physical 
activity.
